Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
For research use only. Not intended for any clinical use.
Cat. No. :
CSC-RO0375
Host Cell :
Ba/F3
Size :
>1x106 frozen cells/vial
Inquire for Price
Cell Line Information
Cell Culture Information
Safety and Packaging
Gene Information
Cat. No.
CSC-RO0375
Description
This cell line is engineered to stably overexpress exogenous human FGFR2-BICC1 fusion protein.
Target Gene
FGFR2-BICC1
Gene Species
Homo sapiens (Human)
Host Cell
Ba/F3
Host Cell Species
Mus musculus (Mouse)
Applications
Drug screening and biological assays
Biosafety Level
2
Size
>1x10^6 frozen cells/vial, 1 mL
Stability
Stable in culture over a minimum of 10 passages
Quality Control
Negative for bacteria, yeast, fungi and mycoplasma.
Growth Conditions
37 °C, 5% CO2
Storage
Liquid nitrogen
Shipping
Dry ice
Thawing & Subculturing Instructions
1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap.
2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely.
3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min.
4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker).
5. Incubate the culture at 37°C with 5% CO2.
6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL.
Freeze Medium
Frozen with 70% medium, 20% FBS, 10% DMSO
Growth Properties
Suspension, round
Freezing Instructions
Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker).
1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium.
6. Aliquot 1 ml of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage.
Mycoplasma
Negative
Format
One frozen vial containing millions of cells
Storage
Liquid nitrogen
Safety Considerations
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship
Dry ice
Target Gene
FGFR2-BICC1
Quick Inquiry
Background
Case Study
Applications
Q & A
Customer Reviews
The FGFR2 (fibroblast growth factor receptor 2) gene encodes a receptor tyrosine kinase that is involved in cell growth, differentiation, and migration. FGFR2 plays a critical role in various developmental processes and is also implicated in several cancers, including breast cancer, gastric cancer, and lung cancer. Fusion genes involving FGFR2, such as FGFR2-BICC1, are rare but have been identified in certain cancers, leading to constitutive activation of the FGFR2 kinase and promoting oncogenic signaling.
The BaF3 cell line, when engineered to express the FGFR2-BICC1 fusion gene, provides a model to study the effects of this specific oncogenic fusion. This stable cell line allows researchers to investigate the molecular mechanisms by which FGFR2-BICC1 contributes to cancer development and to test the efficacy of FGFR2 inhibitors. It is a valuable tool for drug discovery and the development of targeted therapies against cancers driven by FGFR2 fusions.
Case Study 1
Aberrant FGFR2 and FGFR3 transcripts represent critical biomarkers for clinical stratification of intrahepatic cholangiocarcinoma (iCCA) patients. The researchers evaluated the technical performance of routine diagnostic strategies, including fluorescent in situ hybridization (FISH) and next-generation sequencing (NGS), across eight Italian referral institutions using artificially engineered formalin-fixed paraffin-embedded (FFPE) reference samples. These samples were designed to harbor FGFR3(17)-TACC3(11) and FGFR2(17)-BICC1(3) rearrangements, as well as unbalanced FGFR2. Nucleic acids were extracted and analyzed according to each institution's internal workflow, and the presence of FGFR fusions and copy number variations was assessed at both RNA and DNA levels. The Creative Biogene BaF3 FGFR2(17)-BICC1(3) cell line was utilized as a reference standard to ensure reproducibility, supporting robust evaluation of diagnostic assays for molecular profiling in iCCA.
Figure 1. All participating centers successfully detected FGFR2(17)-BICC1(3) and FGFR3(17)-TACC3(11) fusions, with variations in detection of FGFR2 rearrangements and CNVs depending on assay type and sample preparation. (Pepe F, et al., 2025)
Background
This multicenter Italian study evaluated the technical performance of diagnostic FGFR1-3 testing strategies using artificial reference FFPE samples mimicking cholangiocarcinoma specimens. Eight institutions analyzed FGFR2/3 rearrangements with their routine workflows. All laboratories successfully detected FGFR3(17)-TACC3(11) and FGFR2(17)-BICC1(3) aberrant transcripts. Comprehensive genomic profiling assays demonstrated higher sensitivity for uncommon fusions such as FGFR2(3)-CD44(1) compared with targeted NGS panels. The study emphasizes that NGS is the most suitable approach for FGFR molecular profiling and highlights the importance of harmonized ring trials and preanalytical quality for optimizing clinical stratification of intrahepatic cholangiocarcinoma patients. Key Findings
All eight participating institutions successfully identified FGFR3(17)-TACC3(11) and FGFR2(17)-BICC1(3) aberrations in artificial reference samples, demonstrating high interlaboratory reproducibility for these recurrent fusions using NGS-based workflows. Three institutions using comprehensive genomic profiling (CGP) also detected FGFR2(3)-CD44(1) on RNA, while the majority identified FGFR2 copy-number variations on DNA. Notably, CGP assays outperformed targeted panels in detecting rare FGFR2 fusion partners (sensitivity 100% vs 12.5%). Preanalytical conditions significantly impacted nucleic acid yield and fragmentation: cell resuspension provided higher DNA/RNA amounts and integrity than FFPE cell blocks. RT-PCR confirmed results in one institution. The study validates the rationale for combined DNA/RNA NGS analysis and highlights the pivotal role of harmonized quality-control programs to improve FGFR testing accuracy and optimize personalized therapy for intrahepatic cholangiocarcinoma patients. Contribution
Creative Biogene provided the engineered BaF3 cell line (FGFR2(17)-BICC1(3)) used to generate validated reference specimens, enabling multicenter harmonization of FGFR testing.
(1)Drug Screening and Development: The Human FGFR2-BICC1 Stable Cell Line in BaF3 cells is pivotal for the development and screening of targeted cancer therapies. FGFR2 (Fibroblast Growth Factor Receptor 2) mutations and fusions, such as FGFR2-BICC1, have been implicated in various cancers, including breast, gastric, and lung cancers. This cell line enables researchers to test the efficacy of FGFR inhibitors, which can lead to the development of new cancer therapeutics that specifically target these aberrations.
(2)Molecular Pathway Analysis: Utilizing this cell line, scientists can dissect the signaling pathways activated by the FGFR2-BICC1 fusion protein. This is crucial for understanding the oncogenic mechanisms driving tumor growth and metastasis. Insights gained from these studies can inform the development of combination therapies that target multiple pathways, potentially overcoming resistance to single-agent therapies.
(3)Genetic Studies: The cell line serves as a model for studying the genetic and epigenetic alterations introduced by the FGFR2-BICC1 fusion. This includes investigating the impact of these alterations on gene expression, protein function, and cellular behaviors like proliferation, differentiation, and apoptosis. Such studies can provide a deeper understanding of the role of FGFR2 fusions in cancer and identify potential biomarkers for diagnosis and prognosis.
Customer Q&As
How does the Human FGFR2-BICC1 Stable Cell Line - BaF3 enable researchers to understand the pathological implications of the FGFR2-BICC1 fusion in cancer biology?
A: This cell line provides a model system to study the FGFR2-BICC1 fusion gene's contribution to oncogenic signaling pathways. It allows for the assessment of downstream effects on cell proliferation, survival, and differentiation, which are key processes in tumorigenesis.
What are the potential applications of the Human FGFR2-BICC1 Stable Cell Line - BaF3 in the context of personalized cancer therapy?
A: By utilizing this cell line, researchers can test the efficacy of targeted therapies against the FGFR2-BICC1 fusion, such as FGFR inhibitors, which may lead to personalized treatment strategies for patients harboring this genetic alteration.
Which molecular assays would be most effective for validating the expression and function of the FGFR2-BICC1 fusion protein in the Human FGFR2-BICC1 Stable Cell Line - BaF3?
A: Western blotting can be used to validate the expression of the fusion protein, while functional assays, such as phosphorylation assays, can determine its kinase activity. Additionally, luciferase reporter assays may be utilized to study the transcriptional activity regulated by the FGFR2-BICC1 signaling.
Could the Human FGFR2-BICC1 Stable Cell Line - BaF3 be used to investigate the potential for resistance development to FGFR2-targeted therapies?
A: Absolutely. This cell line can serve as a platform for long-term drug treatment studies to identify potential mechanisms by which cancer cells may develop resistance to FGFR2 inhibitors, which is critical for the development of second-line therapies.
What role might the Human FGFR2-BICC1 Stable Cell Line - BaF3 play in the high-throughput screening for novel compounds that can disrupt the FGFR2-BICC1 fusion protein's activity?
A: The cell line could be used in high-throughput assays to identify compounds that inhibit the kinase activity of the fusion protein or its downstream signaling. This could accelerate the discovery of new drugs that specifically target the molecular abnormalities associated with the FGFR2-BICC1 fusion.
Ask a Question
If your question is not addressed through these resources, you can fill out the
online form below and we will answer your question as soon as possible.
Customer Reviews
High expression of FGFR2-BICC1
The Human FGFR2-BICC1 Stable Cell Line - BaF3 has been engineered to overexpress the FGFR2-BICC1 fusion gene consistently. This results in a stable and reproducible platform that is crucial for studying the biochemical and physiological functions of this gene fusion, making it particularly valuable for research into signal transduction pathways where FGFR2-BICC1 is implicated.
United Kingdom
Robust reproducibility
Consistency is key in scientific experiments. The Human FGFR2-BICC1 Stable Cell Line - BaF3 offers robust reproducibility, ensuring that experiments can be repeated with the same conditions leading to comparable results. This stability is beneficial for longitudinal studies requiring repeated measurements under consistent conditions.
Germany
Ready-to-use format
This cell line comes in a format that is easy to culture and maintain, reducing the need for extensive technical training. The Human FGFR2-BICC1 Stable Cell Line - BaF3 allows us to focus more on their experimental designs and less on cell preparation, streamlining the research process.
French
Saves time in experimental setup
Using the Human FGFR2-BICC1 Stable Cell Line - BaF3 can significantly cut down on the time typically required for cell line development and genetic engineering. We can bypass these initial steps and proceed directly to their experimental investigations, which is particularly advantageous in fast-paced research environments where time is critical.
United States
Write a Review
Write a review of your use of Biogene products and services in your research. Your
review can help your fellow researchers make informed purchasing decisions.